E Lubos
Overview
Explore the profile of E Lubos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ludwig S, Kalbacher D, Schofer N, Schafer A, Koell B, Seiffert M, et al.
Clin Res Cardiol
. 2020 Oct;
110(3):411-420.
PMID: 33074368
Aims: Transcatheter mitral valve replacement (TMVR) with dedicated devices promises to fill the treatment gap between open-heart surgery and edge-to-edge repair for patients with severe mitral regurgitation (MR). We herein...
2.
Kalbacher D, Ludwig S, Schofer N, Schirmer J, Reichenspurner H, Conradi L, et al.
Eur Heart J
. 2019 Oct;
40(38):3137-3139.
PMID: 31589329
No abstract available.
3.
Hunlich M, Lubos E, Beuthner B, Puls M, Bleckmann A, Beissbarth T, et al.
Biomed Res Int
. 2018 May;
2018:6817832.
PMID: 29725600
Positive results of MitraClip in terms of improvement in clinical and left ventricular parameters have been described in detail. However, long-term effects on secondary pulmonary hypertension were not investigated in...
4.
Bickel C, Schnabel R, Zengin E, Lubos E, Rupprecht H, Lackner K, et al.
Nutr Metab Cardiovasc Dis
. 2016 Oct;
27(2):168-175.
PMID: 27773468
Background And Aims: Whether single nucleotide polymorphisms (SNPs) of homocysteine metabolism enzymes influence the rate of cardiovascular (CV) events in coronary artery disease (CAD) patients remains controversial. Methods And Results:...
5.
Schlitt A, Lubos E, Guha M, Hegeler-Molkewehrum C, Sudau M, Schmidt H
Herz
. 2016 Jun;
42(2):176-185.
PMID: 27349588
Many patients with moderate to severe mitral regurgitation cannot be subjected to surgical therapy due to their multimorbidity. For these patients, MitraClip® implantation is a therapeutic alternative.The aim of this...
6.
Schafer U, Conradi L, Diemert P, Deuschl F, Schofer N, Seiffert M, et al.
Minerva Cardioangiol
. 2015 Jul;
63(5):359-69.
PMID: 26198875
The Symetis ACURATE TA and ACURATE neo technology is a novel transcatheter heart valve for treatment of aortic valvular stenosis. This review illustrates the implantation steps, which are designed for...
7.
Tregouet D, Schnabel R, Alessi M, Godefroy T, Declerck P, Nicaud V, et al.
J Thromb Haemost
. 2008 Nov;
7(1):49-57.
PMID: 19017260
Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association...
8.
Lowe T, Lubos E
J Psychiatr Ment Health Nurs
. 2008 Nov;
15(10):857-63.
PMID: 19012677
Weight gain associated with treatment with atypical antipsychotic medication has been widely recognized as a risk factor for the development of diabetes and cardiovascular diseases. A systematic search was conducted...
9.
Morange P, Blankenberg S, Alessi M, Bickel C, Rupprecht H, Schnabel R, et al.
J Thromb Haemost
. 2007 Jan;
5(3):475-82.
PMID: 17204132
Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble...
10.
Blankenberg S, Tiret L, Bickel C, Schlitt A, Jungmair W, Genth-Zotz S, et al.
Z Kardiol
. 2004 Apr;
93 Suppl 4:IV16-23.
PMID: 15085362
Background: Various functional polymorphisms of the cholesteryl ester transfer protein ( CETP) gene influence CETP activity and the concentration of high-density lipoprotein (HDL) cholesterol. Beside other functional variants mainly the...